Adriamycin Inhibitor CAS No. 25316-40-9

Cat. No.	Name	Size	Price
KI0292	Adriamycin	10 mg	$160
	Adriamycin	25 mg	$400
	Adriamycin	100 mg	$1120

Chemical Characteristic

Product Name	Adriamycin
Synonyms	Doxorubicin
CAS No.	25316-40-9
Molecular Weight	579.98
Formula	C₂₇H₂₉NO₁₁.HCl
Chemical Name	(8S,10S)-10-((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydro-2H-pyran-2-yloxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione hydrochloride
Smiles	c1ccc2c(c1OC)C(=O)c1c(C2=O)c(c2c(c1O)[C@H](C[C@@](C2)(C(=O)CO)O)OC1O[C@H]([C@H]([C@H](C1)N)O)C)O Cl
Chemical Structure

Biological activities

Adriamycin is an antibiotic anthracycline that inhibits DNA topoisomerase II (TOP2). Adriamycin blocks the synthesis of DNA by intercalating into the DNA strand. Adriamycin induces DNA damage and apoptosis. The adriamycin IC50 value is ??00 µM and 7.29 µM in drug-resistant HEp2A and HEp2 cells, respectively.^[1] Adriamycin (40 nM) has a marginal effect on the survival of CD138+ cells (100% untreated vs 83.25% adriamycin treated). Co-treatment of butyrate (600 µM) and adriamycin (40 nM) significantly reduce the survival of CD138⁺ cells (43.42%).^[2] Adriamycin (0.5 and 1 µM) inhibits AMP-activated protein kinase (AMPK) phosphorylation at Thr¹⁷² and concomitantly reduces acetyl-CoA carboxylase (downstreamtarget of AMPK) phosphorylation at the Ser⁷⁹ in mouse embryonic fibroblasts (MEFs) after 16 hours treatment. Adriamycin (1 µM) markedly reduces the levels of p-AMPK and phospho-acetyl-CoA carboxylase and increases the levels of p53 with increased detection of cleaved caspase-3 after 16 hours incubation in H9C2 cardiomyocytes.^[3] Adriamycin (345 nM) up-regulats CycG2 expression up to 5-fold within the first 4 hours of treatment and remains at elevated levels in cultures treated for 24 hours in the immortalized non-transformed breast epithelial cell line MCF10a. A comparable response is also observed in similarly treated MCF7, NIH3T3 and U2OS cells with adriamycin. Adriamycin (345 nM) increases 63% CycG2 abundance at centrosomes but doesn?? alter the signal intensity for the integral centrosomal protein γ-tubulin. Moreover, adriamycin-induced CycG2 up-regulation follows activation of the ATM signaling pathway but precedes accumulation of cells at the G2-phase checkpoint.^[4] In an MCF7 breast cancer xenograft model, adriamycin (1.5 mg/kg by intraperitoneal injection) signi?cantly inhibits tumor growth of 48%, and cotreated with seliciclib and adriamycin further inhibits tumor growth of 70% relative to the vehicle control group.^[5] In the human breast carcinoma cell line MDA-MB-231 (MB231) xenograft, adriamycin in combination with adenoviral MnSOD (AdMnSOD) plus 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) has the greatest effect in decreasing the volumes of MB231 tumors (from 1100 mm3 in controls to 64 mm3 in combination group) and prolonging survival of mice.^[6]

Protocols

Adriamycin is prepared in H2O and kept at 4 °C for up to 1 month. ^[5]

References

[1] Harbottle A, et al. Role of glutathione S-transferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance. Int J Cancer. 2001, 92(6):777-783. [2] Cheriyath V, et al. Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma. Br J Cancer. 2011, 104(6):957-967 [3] Wang S, et al. Inhibition of AMP-activated protein kinase α (AMPKα) by doxorubicin accentuates genotoxic stress and cell death in mouse embryonic fibroblasts and cardiomyocytes: role of p53 and SIRT1. J Biol Chem. 2012, 287(11):8001-8012. [4] Zimmermann M, et al. Elevated cyclin g2 expression intersects with DNA damage checkpoint signaling and is required for a potent g2/m checkpoint arrest response to doxorubicin. J Biol Chem. 2012, 287(27):22838-22853. [5] Appleyard MV, et al. Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model. Int J Cancer. 2009, 124(2):465-472. [6] Sun W, et al. Enhancing the antitumor activity of adriamycin and ionizing radiation. Cancer Res. 2009, 69(10):4294-4300. [7] Fabian MA, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol. 2005, 23(3): 329-336.

Please click here to fill online order form, and we will make sure to supply you product with detail information. This process usually takes between 24 to 48 hours, depending on products stock avaliability. All inquires and subsequent projects are handled in the strictest confidence and will be backed by a confidentiality agreement if required.

KareBay^TM provides scientists and clinicians with a wide range of biotechnological products and science lab supplies for chemical research and analyzing life processes. KareBay's extensive capabilities include commercializing reagents and kits, manufacturing biotech products and providing contract research services to organizations worldwide. Our many global labs, offices, and business partners enable KareBay to extend its products and services to its customer base around the world.

Our products are used for research, laboratory and further evaluation purposes. They are not for human use.

About

KareBay^TM Biochem
Sitemap
Blog

Custom Services

Organic Synthesis
Peptide Synthesis
Antibody Production
Protein Expression
Bioconjugation Service
Immunoassry Service
Molecular Biology Services
Oligonucleotides Synthesis
RNA Synthesis Service
cGMP Peptide Synthesis Services
cGMP Organic Synthesis Services

Biochemical Products

Small Molecule Inhibitors
Bioactive Compounds
Primary Antibodies
Peptides
Amino Acids
Reagents
Fluorescent dyes
Intermediates
PCR

KareBay^TM Biochem, Inc.
11 Deer Park Drive, Suite 102A
Monmouth Junction, NJ 08852

Telephone

: 732-823-1545

Fax

: 732-823-1349

product@karebaybio.com
service@karebaybio.com
support@karebaybio.com